aeruginosa—one of the most prevalent infection-causing bacteria in cystic fibrosis—and evidence of phage-resistant bacteria having reduced pathogenicity in the nine adults treated with this ...

In a recent study, however, Yale scientists describe a new method for quantifying the host-attachment dynamics of several phage species—including some that target key bacterial pathogens ...

“The phenomenon isn’t just happening in developing nations,” says Richard Honour, president and CEO of Phage Therapeutics International, a fledgling company in Bothell, Washington.

The US government has provided almost $24 million in funding to Locus Biosciences to support a mid-stage trial of LBP-EC01, a CRISPR-engineered bacteriophage therapy in development for resistant ...

Recurrent infections with Pseudomonas aeruginosa are common and lead to worse clinical outcomes. One of the promising avenues of new treatments is phage therapy. In this project, we aim to increase ...

Temperature stability testing of the vB_SmaS_QH3 phage was performed following a previously described methodology with appropriate adaptations (Han et al., 2021). The phage was diluted to 10 8 PFU/mL ...

However, the strong evolutionary pressure exerted by their viral predators has led bacteria to evolve a remarkable variety of anti-phage defense mechanisms. The emergence of next-generation sequencing ...